International Journal of Scientific Research & Engineering Trends
Volume 12, Issue 3, May-Jun-2026, ISSN (Online): 2395-566X

USFDA Guidelines: Regulatory Requirements for Combination Products Involving Drugs, Devices, and Biologics

Kavade Shirisha, K. Someshwar
University college of pharmaceutical sciences, Palamuru university, Mahabubnagar, Telangana-509001, India.

Abstract- Combination products, which are a new class of treatments that present difficult regulatory issues, are made up of a combination of medications, devices, and/or biological products. The United States Food and Drug Administration's (USFDA) regulatory framework for the categorization, approval, and supervision of combination products is examined in this thesis. Key provisions under 21 CFR Part 3 are highlighted, along with the Office of Combination Products' (OCP) function, the principal mode of action (PMOA) determination procedure, and premarket submission paths such as NDA, BLA, and PMA/510(k). To demonstrate how recommendations are applied in practical situations, case studies and regulatory precedents are examined. In order to expedite product development and guarantee compliance, the study emphasizes the significance of interdisciplinary cooperation and early regulatory engagement.

Keywords- USFDA, PMOA, NDA, BLA, Biologics.

I. INTRODUCTION

Combination products integrate drugs, biologics, and medical devices into a single therapeutic system to improve patient compliance, safety, and treatment efficacy. Advances in biotechnology, nanotechnology, pharmacogenomics, and biomedical engineering have accelerated the development of these innovative healthcare products, making them an important component of modern therapeutics. According to 21 CFR 3.2(e), combination products may exist as single-entity products, co-packaged products, or cross-labelled products intended for combined use. Common examples include drug-eluting stents, insulin injector pens, pre-filled syringes, and antibody-drug conjugates, all of which enhance therapeutic precision and patient convenience.

The hybrid nature of combination products creates unique scientific, manufacturing, and regulatory challenges because each constituent part is governed by different regulatory requirements. To manage these complexities, the United States Food and Drug Administration (USFDA) established the Office of Combination Products (OCP), which is responsible for product classification, jurisdiction assignment, and coordination among regulatory canters. The regulatory pathway is primarily determined by the product's Primary Mode of Action (PMOA), which identifies the component providing the main therapeutic effect and assigns oversight to CDER, CBER, or CDRH accordingly.

In addition to meeting requirements related to quality, safety, and efficacy, manufacturers must address issues such as integrated quality systems, labelling, risk management, human factor studies, and post-marketing surveillance. Despite these challenges, combination products offer significant advantages, including targeted drug delivery, reduced systemic toxicity, improved therapeutic outcomes, and personalized treatment approaches. Consequently, a robust and scientifically harmonized regulatory framework is essential to support innovation while ensuring patient safety and product effectiveness.

II. METHODOLOGY

USFDA Regulatory Framework

1. Office of Combination Products (OCP)

The Office of Combination Products (OCP) was established in 2002 by the United States Food and Drug Administration (USFDA) under the statutory mandate of Section 563 of the Federal Food, Drug, and Cosmetic Act (FDCA). The formation of OCP represented a pivotal shift in addressing the complexities of combination product regulation, where products incorporate components from drug, device, and

biologic categories. This methodology adopts a regulatory policy analysis approach to examine the structure, functions, and operational mechanisms of the OCP with respect to combination product oversight.

Established in 2002, the OCP oversees:

- Product classification and jurisdictional decisions (RFD process)
- Coordination among FDA centers
- Timely review of combination product submissions
- To systematically explore the role of OCP in combination product classification and jurisdiction assignment.
- To critically assess the procedures followed by OCP to resolve inter-center jurisdictional disputes through the Request for Designation (RFD) process.
- To evaluate the mechanisms adopted by OCP to ensure timely and coordinated review of combination product submissions.
- To analyze relevant regulatory documents, guidance publications, and real-world case precedents involving OCP decisions.

Analysis of Product Classification and Jurisdictional Decision-Making

The first methodological step involves a comprehensive doctrinal analysis of the Request for Designation (RFD) process under 21 CFR Part 3, which is the formal regulatory route through which sponsors seek a jurisdictional determination for combination products. Key aspects include:

a. **Eligibility Criteria:** Analysis of statutory definitions to determine what constitutes a combination product under 21 CFR 3.2(e).
b. **PMOA Determination:** A systematic evaluation of the Primary Mode of Action (PMOA) principle, which serves as the basis for deciding the lead FDA center.
c. **RFD Timelines:** Assessment of the 60-day decision period stipulated under the regulations and any documented exceptions.
d. **Legal Precedents:** Review of past publicly available RFD decisions to identify decision trends and product classification rationales.

Evaluation of Inter-Center Coordination Mechanisms

This component focuses on how OCP facilitates cooperation among the three primary FDA review centers:

- CDER (Center for Drug Evaluation and Research): Drug-led product review.
- CBER (Center for Biologics Evaluation and Research): Biologic-led product review.
- CDRH (Center for Devices and Radiological Health): Device-led product review.

Methodological tools include:

Document Analysis: Review of OCP annual reports and FDA guidance documents illustrating coordination practices.

Process Flow Mapping: Development of regulatory flowcharts to depict how OCP channels combination product submissions across centers.

Collaborative Review Case Studies: Case-based analysis of products subjected to joint reviews, such as drug-eluting stents (CDER/CDRH collaboration) and cellular immunotherapy devices (CBER/CDRH).

Critical Review of Timely Review Initiatives

This section assesses the effectiveness of OCP in expediting the review of combination product submissions, focusing on:

- Performance Metrics: Review of OCP's published performance reports and timelines for handling RFDs and premarket submissions.
- Statutory Timelines Enforcement: Evaluation of the adherence to prescribed statutory deadlines, including:
- 60 days for RFD determination.
- Review timeline targets for NDAs, BLAs, PMAs, and hybrid submissions.
- Use of Inter-Center Agreements (ICAs): Analysis of inter-center agreements as tools for ensuring procedural consistency and timeliness.
- COVID-19 Pandemic Fast-Track Measures: Assessment of recent accelerated pathways facilitated by OCP during public health emergencies.

Data Sources and Analytical Tools

The methodology relies on:

- Primary Sources: Federal Register notices, FDA regulations (21 CFR Parts 3, 314, 601, 814), OCP guidance documents, and case law.
- Secondary Sources: Peer-reviewed academic articles, white papers by industry organizations, and government reports.

- Qualitative Content Analysis: Identification of recurring themes, procedural bottlenecks, and jurisdictional inconsistencies.
- Comparative Jurisdictional Analysis: Cross-comparison with other regulatory frameworks (e.g., EMA's Borderline and Classification Committee) to benchmark OCP's performance.

Jurisdiction and Center Assignments & Regulatory Pathways

The regulatory oversight of combination products by the USFDA is primarily determined by the product's Primary Mode of Action (PMOA). Based on the dominant therapeutic action, the appropriate lead center is assigned for review and approval. The Center for Drug Evaluation and Research (CDER) regulate products in which the primary action is due to a chemical drug effect, while the Center for Biologics Evaluation and Research (CBER) oversee products whose principal action involves immunologic or biological activity. Products with predominantly mechanical or physical action are regulated by the Center for Devices and Radiological Health (CDRH). Accordingly, the regulatory approval pathway varies depending on the dominant component of the product. Drug-dominant combination products are generally submitted through the New Drug Application (NDA) pathway under 21 CFR 314, biologic-dominant products follow the Biologics License Application (BLA) pathway under 21 CFR 601, and device-dominant products are reviewed through the Premarket Approval (PMA) or 510(k) pathways under 21 CFR 814 and 21 CFR 807, respectively.

Investigational Applications

- IND: Required for drug/biologic components
- IDE: Required for investigational device components
- Hybrid applications may be necessary depending on PMOA

Quality and Manufacturing Requirements

cGMP and QSR Integration

Combination products must comply with both:

- 21 CFR Part 210/211 (drugs/biologics - cGMP
- 21 CFR Part 820 (devices - QSR)

Final Rule for cGMP (2013)

Labeling, Postmarket Surveillance, and Risk Management

- Labeling Requirements

Labeling must reflect the intended use, risks, and instructions consistent with the combination's PMOA.

Postmarket Requirements

Includes:

- Adverse event reporting under 21 CFR 803 (devices), 312 (drugs), and 600 (biologics)
- Field corrective actions and recalls
- Post-approval studies or REMS (if applicable)

Case Studies

Example: Drug-Eluting Stents

PMOA: Drug action on vascular tissue → CDER-led

Reviewed collaboratively with CDRH

Table: 1 Case Study: Drug-Eluting Stents (DES)

Parameter	Description
Product Type	Combination Product – A drug-eluting stent (DES) combines a medical device (stent) with a pharmaceutical drug coated on the surface of the stent.
Primary Mode of Action (PMOA)	The primary therapeutic effect of the combination product is attributed to the drug component, which acts locally on the vascular tissue to prevent restenosis (re-narrowing of the artery). The stent acts primarily as a mechanical support device, but the drug's pharmacological action plays the primary role in therapeutic benefit.
Center of Lead Jurisdiction	Due to the drug's action being primary, the Center for Drug Evaluation and Research (CDER) takes primary jurisdiction and leads the regulatory review process.
Collaborative Review	Despite CDER leading the review, the Center for Devices and Radiological Health (CDRH) plays a collaborative role in evaluating the device component, including mechanical performance, biocompatibility, and manufacturing quality of the stent.
Regulatory Considerations	- Cross-Center collaboration is essential to ensure comprehensive assessment of both drug and device components.- OCP (Office of Combination Products) plays a key role in jurisdictional assignment and coordinating reviews between CDER and CDRH.- Combination product reviews ensure that safety, efficacy, and quality

Parameter	Description
	standards of both drug and device elements are met.- Regulatory guidance focuses on clinical study designs, quality control of the drug coating process, drug release kinetics, and device mechanical integrity.
Outcome/Impact	Drug-eluting stents have revolutionized cardiovascular care by significantly reducing the risk of restenosis compared to bare-metal stents. The coordinated regulatory approach ensures patient safety and therapeutic efficacy of these high-risk combination products.

Example: Insulin Injector Pen
PMOA: Drug → CDER
Device component cleared via 510(k) before NDA approval

Table: 2 Case Study: Insulin Injector Pen

Parameter	**Description**
Product Type	Combination Product – The insulin injector pen combines a drug product (insulin) with a medical device component (injector pen) designed to facilitate precise and user-friendly drug delivery.
Primary Mode of Action (PMOA)	The primary therapeutic effect of the product is due to the pharmacological action of insulin, which lowers blood glucose levels in diabetic patients. The device component serves as a delivery mechanism to administer the insulin, but it does not provide therapeutic action on its own.
Center of Lead Jurisdiction	The Center for Drug Evaluation and Research (CDER) takes primary jurisdiction over the combination product because the drug component (insulin) provides the Primary Mode of Action (PMOA). CDER is responsible for evaluating the safety, efficacy, and quality of the insulin formulation under the New Drug Application (NDA) or Biologics License Application (BLA) pathways.
Device Component Regulatory Status	- The injector pen device is typically classified as a Class II medical device.- The device component undergoes separate regulatory clearance through the 510(k) premarket notification process under the oversight of the Center for Devices and Radiological Health (CDRH).- The 510(k) clearance is usually granted prior to the NDA or BLA approval, ensuring that the device is safe and effective for its intended use as a delivery system.
Collaborative Review Process	- The Office of Combination Products (OCP) assigns CDER as the lead center, while CDRH contributes through consultative review, particularly focusing on device design, usability studies, human factors engineering, and mechanical performance.- The combined review ensures that both drug-specific and device-specific regulatory requirements are adequately addressed before market approval.
Regulatory Considerations	- Comprehensive assessment includes drug stability within the device, drug-device compatibility, dose accuracy, and patient usability. - Human factors studies are often required to assess user interaction and reduce risk of dosing errors. - Post-market surveillance includes both pharmacovigilance and device adverse event monitoring under 21 CFR Part 4.
Outcome/Impact	Insulin injector pens have transformed diabetes management by offering a convenient, accurate, and user-friendly alternative to traditional vials and syringes. The integrated regulatory pathway, combining drug and device oversight, ensures product quality, therapeutic efficacy, and patient safety.

III. RESULTS AND DISCUSSION

Comparative Regulatory Framework: Drugs, Devices, Biologics vs Combination Products

This section highlights the regulatory differences when drugs, devices, and biologics are regulated alone versus as part of combination products. Combination products require dual oversight, integrated reviews, and hybrid compliance mechanisms.

Product Type	Standalone Regulation	Combination Product Regulation

Drugs	21 CFR 314 (NDA), 312 (IND), regulated by CDER	Additional device data, reviewed under NDA with CDRH input if applicable
Devices	21 CFR 807 (510(k)), 812 (IDE), 814 (PMA), regulated by CDRH	Supplemental pharmacological/biological data required; collaborative reviews
Biologics	21 CFR 601 (BLA), 312 (IND), regulated by CBER	Expanded dossiers with device usability, mechanical testing; integrated BLA reviews

Submission Formats

Combination product submissions are more complex, requiring hybrid data sets:

- Drugs: Common Technical Document (CTD) with device info in Modules 3 and 5.
- Devices: Device format with clinical data incorporated.
- Biologics: CTD adapted with device and delivery system data.

Quality System Requirements (QSR) and cGMP Compliance
Summary of Quality Compliance:

Product Type	**Standalone Quality System**	**Combination Product Compliance**
Drugs	21 CFR 210/211 (cGMP)	cGMP + selective 21 CFR 820 (QSR) requirements
Devices	21 CFR 820 (QSR)	QSR + applicable drug GMP controls
Biologics	21 CFR 210/211/600	Combination of cGMP and QSR standards

Post-Market Surveillance and Risk Management

Aspect	Standalone Regulation	Combination Product Regulation
Adverse Event Reporting	Drugs: 314.80; Devices: 803; Biologics: 600.80	Must comply with both systems based on components
Recalls	Devices: 806; Drugs/Biologics: Voluntary withdrawal	Dual pathways with inter-center coordination
Post-Approval Studies	PMA (devices), REMS (drugs/biologics)	More common with high-risk combination products
Inspections	GMP (drugs), QSR (devices)	Cross-center inspections for both GMP and QSR

Discussion Summary

Combination products introduce regulatory complexity, dual compliance burdens, and heightened post-market vigilance. Compared to standalone products, combination products:

- Require hybrid submission formats
- Must comply with overlapping quality systems
- Face stringent post-market obligations
- Demand inter-center collaboration and integrated regulatory strategies

Regulatory Complexities of Combination Products vs. Standalone Products



Fig : 1 Regulatory Requirements for Combination Products Involving Drugs, Devices, and Biologics

Comparative Regulatory and Developmental Aspects of Combination Products and Standalone Products

Submission Format

Combination products require a hybrid and integrated regulatory submission format involving drug, biologic, and device-related documentation based on the Primary Mode of Action (PMOA). Unlike standalone products that follow a single regulatory pathway, combination product submissions include engineering data, human factors studies, software validation, biocompatibility, and integrated safety information.

Quality Systems Compliance
Combination products must comply with overlapping pharmaceutical cGMP and medical device quality system requirements under 21 CFR Part 4. In contrast, standalone products generally follow a single quality framework with less regulatory integration.

Post-Market Obligations
Post-market surveillance for combination products includes both pharmacovigilance and device vigilance activities such as adverse event reporting, recalls, complaint handling, and performance monitoring. Standalone products typically follow only one surveillance system.

Inter-Center Collaboration and Regulatory Strategy
Combination products often require coordinated review by multiple FDA centers, including CDER, CBER, and CDRH, under the supervision of the Office of Combination Products (OCP). Standalone products are usually reviewed by a single regulatory center.

Clinical and Nonclinical Evidence Requirements
Combination products require broader evidence packages covering therapeutic efficacy, device performance, sterility, usability, compatibility, and risk management. Standalone products generally require category-specific evidence only.

Human Factors and Usability Requirements
Human factors engineering is highly important for combination products, especially patient-operated systems such as autoinjectors and insulin pens, where usability directly impacts dose delivery and patient safety.

Labeling Complexity
Labeling for combination products is more complex because it must integrate medicinal information, device instructions, warnings, storage conditions, activation procedures, and disposal instructions within a single format.

Change Control After Approval
Post-approval changes in device materials, software, suppliers, or formulations may significantly affect combination product performance and often require bridging studies and regulatory reassessment. Standalone products generally involve less complex lifecycle management.

Supply Chain Complexity
Combination products involve multi-component supply chains that may include APIs, sterile components, electronics, plastics, sensors, and software systems, making supplier quality management critical.

Inspection Readiness
Regulatory inspections for combination products are broader in scope and may include sterile manufacturing operations, device assembly, software controls, complaint systems, validation, and CAPA reviews simultaneously.

Risk Management Requirements
Combination products require comprehensive cross-functional risk management addressing dosing errors, contamination, software failures, misuse, and component incompatibility. Standalone products usually involve single-modality risk assessment.

Time to Approval
Combination products often have longer approval timelines because of multidisciplinary reviews, inter-center consultations, and integrated evidence evaluation, whereas standalone products generally follow more predictable review pathways.

Cost of Development
Development costs for combination products are higher due to additional requirements such as device engineering, human factors studies, software validation, packaging qualification, and integrated manufacturing systems.

Global Regulatory Harmonization Challenges
Different countries may classify combination products differently as drug-led or device-led products, creating regulatory harmonization challenges and requiring region-specific submission strategies.

Commercial and Patient Value
Combination products provide significant patient and commercial benefits by improving adherence, convenience, portability, dose accuracy, and therapeutic effectiveness. Examples such as drug-eluting stents, smart inhalers, and autoinjectors highlight their growing importance in modern healthcare.

Case Studies of FDA-Approved Combination Products

This section reviews real-world examples of FDA-approved combination products with a focus on their regulatory strategy, approval timelines, and post-market performance. These cases illustrate diverse Primary Modes of Action (PMOA) and the role of FDA lead centers in the regulatory process.

Summary of Selected Combination Products

Combination Product	PMOA	Lead Center	Regulatory Pathway	Approval Timeline	Post-Market Performance
Drug-Eluting Stent (CYPHER®)	Drug (inhibits restenosis)	CDER + CDRH	NDA (21 CFR 314)	18-24 months	Post-Approval Studies (PAS), MAE reporting
Prefilled Syringe (EpiPen®)	Drug (epinephrine delivery)	CDER	NDA + 510(k)	10-12 months	Device reliability monitoring, recalls history
Autoinjector Pen (HUMIRA® Pen)	Drug (biologic injection)	CDER	BLA + 510(k)	10 months initial, supplements for upgrades	REMS programs, device malfunctions
Cell Therapy + Device (PROVENGE®)	Biologic (cell immunotherapy)	CBER	BLA + device clearance	12 months	REMS, 15-year follow-up registry
Closed-Loop Insulin System (670G®)	Device (automated insulin)	CDRH	PMA (21 CFR 814)	12-18 months	PAS, cybersecurity, software updates

Combination products are an important category regulated by the U.S. FDA, integrating drugs, devices, and biologics into a single therapeutic system to improve efficacy, precision, convenience, and patient adherence. Their rapid growth is driven by increasing chronic diseases, self-administration therapies, biologics, and minimally invasive treatments. Due to their hybrid nature, these products require coordinated regulatory review involving CDER, CBER, CDRH, and the Office of Combination Products. Regulatory evaluation includes not only safety and efficacy, but also device performance, human factors, sterility, packaging integrity, and lifecycle management. Prefilled syringes and autoinjectors have gained significant commercial success because of reduced dosing errors and improved patient compliance. Drug-eluting stents remain a major example of successful device-led combination products, significantly reducing restenosis rates through controlled drug release. Autoinjectors and insulin pens have improved treatment adherence and usability through ergonomic and patient-friendly designs. Inhalation products and transdermal patches further demonstrate the importance of integrating pharmaceutical science with device engineering to optimize therapeutic outcomes. Successful approval of combination products depends on early FDA interaction, robust quality systems, effective human factors studies, and strong post-market surveillance. Overall, combination products continue to drive therapeutic innovation and are expected to expand further with the advancement of smart devices, wearable systems, and AI-assisted drug delivery technologies.

Statistical Overview of FDA Combination Products

Growth Trend of Combination Products (Estimated FDA Market Trend)

Year	Estimated FDA Combination Product Submissions
2015	320
2017	410
2019	520
2021	645
2023	790

- Continuous increase in submissions demonstrates rising industry interest.
- Growth driven by self-administration devices, biologics delivery systems, smart devices, and patient-centric products.
- Auto-injectors and prefilled syringes form the largest segment.
- Regulatory Strategy Overview

Case Study: Drug-Eluting Stents (DES)

Product Category:

Device + Drug Combination Product

Examples:

- Xience Stent
- Cypher Stent
- Resolute Onyx

Components:

- Metallic coronary stent (device)
- Anti-proliferative drug coating such as everolimus or zotarolimus

Purpose:
Used in coronary artery disease to keep arteries open and prevent restenosis.
FDA Regulatory Pathway:

- Lead Center: CDRH
- Submission Type: PMA (Premarket Approval)

Statistical Data:

Parameter	Value
Reduction in restenosis vs bare metal stents	40–70%
Annual global market size	> USD 7 Billion
Typical PMA review time	180–320 days

Case Study: Metered Dose Inhalers (MDI)
Product Category:
Drug + Device
Examples:

- Ventolin HFA
- Symbicort
- Flovent

Components:

- Pressurized canister with drug
- Metered actuator device

Indications:

- Asthma
- COPD

Statistical Reports:

Parameter	**Value**
Global inhaler users	>300 Million
Correct use without training	<50%
Improved control with training devices	+35%

Comparative Statistical Summary of case studies of few examples:

Product Type	**FDA Lead Center**	**Avg Review Complexity**	**Market Growth**
Drug-Eluting Stent	CDRH	Very High	High
Prefilled Syringe	CDER	Moderate	High
Auto-Injector	CDER	High	Very High
Insulin Pen	CDER	High	High
Inhaler	CDER	High	Stable
Patch	CDER	Moderate	Moderate
Drug-Coated Balloon	CDRH	Very High	Growing

FDA-approved combination products represent one of the most advanced areas of healthcare innovation. Products such as drug-eluting stents, auto-injectors, inhalers, insulin pens, and prefilled syringes have significantly improved patient outcomes, convenience, and adherence.

Statistical trends show rising approvals, growing market value, and increasing complexity of submissions. The future of medicine will strongly depend on integrated drug-device-biologic platforms, making combination products a critical focus area for regulatory science and pharmaceutical development.

The regulatory strategy for these products follows FDA's Primary Mode of Action (PMOA) framework. The Office of Combination Products (OCP) determines the lead center and coordinates inter-center collaboration when necessary. Common strategies include synchronized NDA/BLA and device submissions, Request for Designation (RFD) procedures, and adherence to both cGMP (drugs/biologics) and QSR (devices) requirements.

Approval Timelines Observations
Approval timelines for combination products generally extend beyond typical single-product reviews due to cross-center coordination. Fast-track mechanisms and priority reviews are selectively granted, especially in cases of life-threatening conditions or unmet medical needs.

Post-Market Performance Patterns
FDA employs stringent post-market oversight mechanisms, including:

- Adverse Event Reporting (21 CFR 803, 312, 600)
- Risk Evaluation and Mitigation Strategies (REMS)
- Post-Approval Studies (PAS)
- Real-world evidence (RWE) incorporation
- Combination products, especially those with device components, frequently face

post-market modifications, recalls, or additional safety reporting requirements.

Combination products under FDA oversight represent a complex intersection of pharmacological, biological, and device regulatory pathways. While regulatory structures provide robust pre-market and post-market oversight, challenges remain in ensuring continuous product performance. Ongoing advancements in real-world data integration and risk management are enhancing post-market surveillance efficiency.

Expert Insights on Regulatory Challenges and Evolving Trends

To gain practical perspectives on the regulatory framework governing combination products, qualitative insights were gathered from:

- Publicly available expert commentaries from FDA officials
- Industry white papers from regulatory consultants
- Statements from regulatory professionals in conferences and webinars

Published interviews from journals such as Regulatory Focus and Therapeutic Innovation & Regulatory Science

These qualitative inputs supplemented the doctrinal and comparative analysis by providing real-world reflections on the operational strengths and bottlenecks within the FDA regulatory ecosystem for combination products.

IV. CONCLUSION

The present study highlights the evolving and multidisciplinary regulatory framework established by the USFDA for combination products involving drugs, devices, and biologics. The Office of Combination Products (OCP) plays a critical role in coordinating inter-center reviews and determining jurisdiction through the Primary Mode of Action (PMOA). Combination products require integrated regulatory submissions, dual quality system compliance, extensive human factors evaluation, and comprehensive post-market surveillance compared to standalone products. Clinical evidence demonstrates that these products significantly improve patient adherence, usability, dosing accuracy, and therapeutic outcomes.

Products such as drug-eluting stents, autoinjectors, insulin pens, and inhalation systems have shown substantial reductions in medication errors and improved clinical performance. Despite longer development timelines and higher regulatory complexity, combination products provide strong commercial and therapeutic advantages. The increasing adoption of smart devices, AI-enabled systems, wearable injectors, and personalized delivery technologies indicates significant future growth in this sector. However, challenges related to regulatory harmonization, lifecycle management, and integrated quality compliance still remain. Therefore, early regulatory engagement, robust risk management, integrated quality systems, and patient-centered product design are essential for successful approval and sustainable market performance. Overall, combination products represent a major advancement in modern healthcare by integrating pharmaceutical science, engineering, and patient-focused innovation into a unified therapeutic approach.

REFERENCE

1. USFDA. Guidance for Industry and FDA Staff: Early Development Considerations for Innovative Combination Products.
2. 21 CFR Part 3, 210, 211, 820, 314, 601, 803
3. ICH M4, M7, Q8–Q10
4. FDA Combination Products Website: https://www.fda.gov/combination-products
5. Hamilton GS. Antibody-drug conjugates for cancer therapy: The technological and regulatory challenges of developing drug-biologic hybrids. Biologicals. 2015 Sep;43(5):318-32. doi: 10.1016/j.biologicals.2015.05.006. U.S. Food and Drug Administration (FDA). (2020). Guidance for Industry and FDA Staff: Current Good Manufacturing Practice Requirements for Combination Products. Retrieved from https://www.fda.gov/regulatory-information/search-fda-guidance-documents/current-good-manufacturing-practice-requirements-combination-products
6. U.S. Food and Drug Administration (FDA). (2019). Guidance for Industry and FDA Staff: How to Write a Request for Designation (RFD). Retrieved from https://www.fda.gov/combination-products/guidance-regulatory-information/how-write-request-designation-rfd
7. U.S. Food and Drug Administration (FDA). (2023). Office of Combination Products (OCP). Retrieved from https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/office-combination-products

8. Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. §301 et seq. (1938). Governs the regulation of drugs and devices.
9. Public Health Service (PHS) Act, 42 U.S.C. §201 et seq. (1944). Governs the regulation of biologics.
10. Medical Device Amendments of 1976, Pub. L. No. 94-295, 90 Stat. 539 (1976). Establishes the regulatory framework for medical devices in the United States.
11. U.S. Food and Drug Administration (FDA). (2019). Principles of Premarket Pathways for Combination Products. Retrieved from https://www.fda.gov/media/120459/download
12. U.S. Food and Drug Administration (FDA). (2024). Draft Guidance: Human Factors Studies and Related Clinical Study Considerations in Combination Product Development. Retrieved from https://www.fda.gov/combination-products/guidance-regulatory-information/combination-products-guidance-documents
13. U.S. Food and Drug Administration (FDA), Office of Combination Products. (2020). Guidance for Industry and FDA Staff: Current Good Manufacturing Practice Requirements for Combination Products. Retrieved from https://www.fda.gov
14. Rhyne, D., & Ho, A. (2018). Regulatory pathways for combination products. Regulatory Focus. Retrieved from https://www.raps.org
15. Robinson, M., Singh, S., & Patel, N. (2017). Regulatory challenges and innovations in drug-device products. Journal of Medical Devices, 11(3), 031004. https://doi.org/10.1115/1.4036819
16. U.S. Food and Drug Administration (FDA). (2019). Combination Products: Report to Congress. Retrieved from https://www.fda.gov
17. Hunter, A., & Krevolin, M. (2021). Mastering the cGMP puzzle for combination products. FDLI Update, 36(3), 22–27. Retrieved from https://www.fdli.org
18. Maisel, K., Chertok, B., & Langer, R. (2020). Regulatory and technical considerations for injectable drug-device products. Nature Biomedical Engineering, 4, 469–472. https://doi.org/10.1038/s41551-020-0563-1
19. U.S. Food and Drug Administration (FDA). (2015). Postmarket Safety Reporting for Combination Products: Final Rule. Retrieved from https://www.fda.gov
20. Lu, R., Manogue, J., & Goldberg, A. (2016). Drug-device combination product regulation: Global versus USFDA approach. Regulatory Focus. Retrieved from https://www.raps.org
21. Lee, H., & Sun, J. (2022). Trends in FDA oversight of biologic-device combinations. Biomedical Instrumentation Journal, 15(1), 44–52.
22. U.S. Food and Drug Administration (FDA). (2023). Combination Product Review: Intercenter Consult Request Process. Retrieved from https://www.fda.gov